ImmuPharma PLC
  • Announcements
  • About Us
    • About Us
    • Our Team
    • Board of Directors
  • Our Science
    • Our Science
    • ImmuPharma Biotech
    • Key Clinical Investigators
  • Pipeline
    • Pipeline
    • Autoimmunity & Inflammation
    • Anti-Infectives
  • Partnerships & Collaborations
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Analyst Research
    • Interviews
    • Professional advisers
    • Email Alerts
  • Contact
Archives
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
February 23, 2016

Result of GM

Read More
February 15, 2016

First US Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study

Read More
February 15, 2016

First US Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study

Read More
February 05, 2016

Placing and Subscription Raises £8.3 million

Read More
February 05, 2016

Proposed Placing and Subscription and Notice of General Meeting: 22 February 2016

Read More
December 15, 2015

Over 70 Lupus Specialists Gather in Paris for Lupuzor’s™ Phase III Investigators Meeting

Read More
December 07, 2015

Lupuzor™ Pivotal Phase III Trial Recruiting First US Lupus Patients

Read More
November 04, 2015

Lupuzor™ Phase III Pivotal Trial Update

Read More
October 23, 2015

Board Change

Read More
September 30, 2015

Tim McCarthy Appointed as Non-executive Chairman

Read More
September 30, 2015

Interim Results Announcement for the six months ended 30 June 2015

Read More
July 29, 2015

Richard Warr

Read More
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 24
  • Keep up-to-date with email alerts

  • @immupharma

Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2022 | All rights reserved